Peter A. Thompson

This profile gathers the share dealings of Peter A. Thompson across 6 companies, led by Sionna Therapeutics, Inc., Alpine Immune Sciences, Inc. and Edgewise Therapeutics, Inc. The record holds 29 filings, for trades running from 15 June 2021 to 7 July 2026.

Both buying and selling appear: 6 purchases worth €24.9M, against 17 sales worth €52.9M. On balance, insiders were net sellers of €28.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 2 share grants and 1 option exercise. 2026 to date brings no purchases and 7 sales.

In size, the median ticket on the buying side is €4.6M. Of 6 purchases, 6 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 9 July 2026: an open-market sale of €3.4M, in Sionna Therapeutics, Inc. The last insider purchase was made public on 4 April 2025, 562 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.